Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response (AMELIORATE)

NCT01530711 Phase 4 UNKNOWN

Observe the effect of terlipressin on renal function in patients with SHR type I adjusting the dose based on hemodynamic response.

Details

Lead sponsor	Pere Gines
Phase	Phase 4
Status	UNKNOWN
Enrolment	40
Start date	2012-04
Completion	2016-12

Conditions

• Cirrhosis
• Hepatorenal Syndrome Type I

Interventions

• Terlipressin and albumin

Primary outcomes

• Changes in arterial pressure and creatinine — 4 months

Countries

Spain